Thermo Fisher sells microbiology biz to Astorg for $1.075 B

robot
Abstract generation in progress

Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg, a pan-European private equity firm, for approximately $1.075 billion. The microbiology business, which generated $645 million in revenue in 2025, offers antimicrobial susceptibility testing and culture media solutions. This sale is expected to close in the second half of 2026 and reflects Thermo Fisher’s strategy to deploy capital to create shareholder value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin